Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Michael Donovan nominated for election at the 2026 Annual Meeting, adding 36 years of life-sciences audit and finance experience.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Michael Donovan nominated for election at the 2026 Annual Meeting, adding 36 years of life-sciences audit and finance experience
- Donovan’s background includes IPOs, financings, M&A, licensing agreements, spin-outs and product launches
- John Fallon, M.D. retiring from the Board at the Annual Meeting after serving since 2016
- Retirement attributed to board refreshment and succession planning, not disagreement with Collegium
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.